CCL24抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human lymphoma tissue, Primary antibody: P00247(CCL24 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

CCL24. also known as eotaxin-2. is a chemokine belonging to the CC subfamily that plays a critical role in immune regulation and inflammatory responses. It binds to the CCR3 receptor, primarily expressed on eosinophils, basophils, and Th2 lymphocytes, facilitating their migration to sites of inflammation or injury. CCL24 is implicated in the pathogenesis of various inflammatory and fibrotic diseases, including asthma, atopic dermatitis, idiopathic pulmonary fibrosis (IPF), and liver fibrosis, where excessive eosinophil recruitment perpetuates tissue damage.

CCL24 antibodies are therapeutic or diagnostic tools designed to specifically target and neutralize CCL24 activity. By blocking CCL24-CCR3 interactions, these antibodies inhibit the chemotaxis of pro-inflammatory cells, thereby reducing chronic inflammation and fibrosis. Monoclonal antibodies against CCL24 have shown promise in preclinical studies, particularly in models of fibrotic disorders and eosinophil-mediated diseases. For instance, they may attenuate collagen deposition in IPF or mitigate allergic responses in asthma.

Additionally, CCL24 overexpression has been linked to certain cancers, where it may promote tumor progression and immunosuppression. Antibodies targeting CCL24 could thus have dual utility in oncology and immunology. Current research focuses on optimizing antibody specificity, pharmacokinetics, and safety profiles, with some candidates advancing to early-phase clinical trials. Overall, CCL24 antibodies represent a potential therapeutic avenue for diseases driven by dysregulated chemokine signaling.